Medizinische Maßnahmen zur Demenzprävention

ZUSAMMENFASSUNG

Körperliche Erkrankungen wie arterielle Hypertonie, Typ-2-Diabetes-mellitus, Hyperhomozysteinämie und Hypercholesterinämie sind mit einem erhöhten Risiko für die Entwicklung einer Alzheimer-Demenz verbunden. Sie treten gehäuft bei Personen auf, die an Demenzprävention interessiert sind. Ein Nutzen der Behandlung dieser Risikofaktoren zur Demenzprävention erscheint wahrscheinlich, ist aber unterschiedlich gut belegt. Die Wirksamkeit der einzelnen Risikofaktoren und der präventive Nutzen ihrer Behandlung hängt vermutlich von verschiedenen Merkmalen der betreffenden Person ab, z. B. Geschlecht, Alter, medizinische Vorgeschichte und Apolipoprotein E-Genotyp. Daher sollten sinnvolle Präventionsempfehlungen im Sinne einer personalisierten Medizin diese Variablen berücksichtigen.

ABSTRACT

Physical diseases such as arterial hypertension, type 2 diabetes mellitus, hyperhomocysteinemia, and hypercholesterolemia are associated with an increased risk of developing Alzheimer’s dementia. These diseases are frequently found in persons interested in dementia prevention. An advantage in the treatment of these risk factors for dementia prevention seems likely but has different degrees of evidence. The impact of the individual risk factors and the preventive benefits of their treatment may depend on various characteristics of the person concerned, e. g. sex, age, medical history and apolipoprotein E genotype. Therefore, sensible prevention recommendations in terms of personalized medicine should take these variables into account.

Schlüsselwörter

Körperliche Erkrankungen - Alzheimer-Demenz - Risikofaktor - medizinische Intervention

Key words

Physical illnesses - Alzheimer’s dementia - risk factor - medical intervention

• Literatur

• 1 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. The Lancet Neurology 2011; 10 (09) 819-28 doi: 10.1016/S1474-4422(11)70072-2
• 2 Norton S, Matthews FE, Barnes DE. et al Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. The Lancet Neurology 2014; 13 (08) 788-94 doi: 10.1016/S1474-4422(14)70136-X
• 3 Luck T, Riedel-Heller SG, Luppa M. et al Risk factors for incident mild cognitive impairment--results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Acta Psychiatr Scand 2010; 121 (04) 260-72 doi: 10.1111/j.1600-0447.2009.01481.x
• 4 Barrett-Connor E, Edelstein SL, Corey-Bloom J. et al Weight loss precedes dementia in community-dwelling older adults. J Nutr Health Aging 1996; 44: 1147-52
• 5 Jost BC, Grossberg GT. The Evolution of Psychiatric Symptoms in Alzheimers Disease: A Natural History Study. JAGS 1996; 44: 1078-81
• 6 Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurology 2005; 4: 487-99
• 7 Deane R, Wo Z, Zlokovicz BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35 (Suppl. 01) 2628-31
• 8 Zhang J, Chen C, Hua S. et al An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract 2017; 124: 41-7
• 9 Farris W, Mansourian S, Chang Y. et al Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162-7
• 10 Binder J, Marczak A, Adler G. Glycilated Hemoglobin and Cognitive Impairment. Int J Neurol Neurother 2017; 4: 2 doi: 10.23937/2378–3001/1410069
• 11 Smith AD, Refsum H, Bottiglieri T. et al Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis 2018; 62 (02) 561-70 doi: 10.3233/JAD-171042
• 12 Ravaglia G, Forti P, Maioli F. et al Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005; 82: 636-45
• 13 Clarke R, Smith AD, Jobst KA. et al Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-55
• 14 Tucker KL, Quiao M, Scott T. et al High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr 2005; 82: 627-35
• 15 Li R, Wang T-J, Lyu P-Y. et al Effects of Plasma Lipids and Statins on Cognitive Function. Chin Med J 2018; 131 (04) 471-6 doi: 10.4103/0366-6999.225062
• 16 Chauhan NB. Membrane dynamics, cholesterol homeostasis, and Alzheimer’s disease. J Lipid Res 2003; 44: 2019-29
• 17 Adler G, Marczak A, Binder J. Cognitive Blackouts in Mild Cognitive Impairment and Alzheimer’s Dementia. Dement Geriatr Cogn Dis Extra 2018; 8 (01) 72-6 doi: 10.1159/000486478
• 18 Rikli RE, Jones CJ. Development and validation of a functional fitness test for community-residing older adults. J Aging Phys Act 1999; 7: 129-61
• 19 Rocca WA, Petersen RC, Knopman DS. et al Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011; 7 (01) 80-93 doi: 10.1016/j.jalz.2010.11.002
• 20 Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ. et al Is dementia incidence declining?: Trends in dementia incidence since, 1990 in the Rotterdam Study. Neurology 2012; 78: 1456-63
• 21 Rothwell PM, Coull AJ, Giles MF. et al Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from, 1981 to 2004 (Oxford Vascular Study). The Lancet 2004; 363 9425 1925-33 doi: 10.1016/S0140-6736(04)16405-2
• 22 Feigin VL, Lawes CMM, Bennett DA. et al Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. The Lancet Neurology 2009; 8 (04) 355-69 doi: 10.1016/S1474-4422(09)70025-0
• 23 Peters R, Beckett N, Forette F. et al Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet Neurology 2008; 7 (08) 683-9 doi: 10.1016/S1474-4422(08)70143-1
• 24 Haag MD, Hofman A, Koudstaal PJ. et al Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80: 13-7
• 25 Durga J, van Boxtel MPJ, Schouten EG. et al Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007; 369: 208-16
• 26 Ngandu T, Lehtisalo J, Solomon A. et al A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet 2015; 385 9984 2255-63 doi: 10.1016/S0140-6736(15)60461-5
• 27 Anstey KJ, Peters R. Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research. J Prev Alzheimers Dis 2018; 5 (01) 2-4 doi: 10.14283/jpad.2017.27
• 28 Villeneuve S, Brisson D, Marchant NL. et al The potential applications of apolipoprotein E in personalized medicine. Front Aging Neurosci 2014; 6 (154) 1-11
• 29 Berkowitz CL, Mosconi L, Rahman A. et al Clinical Application of APOE in Alzheimer’s Prevention: A Precision Medicine Approach. J Prev Alzheimers Dis 2018; 5 (04) 245-52 doi: 10.14283/jpad.2018.35
• 30 Rodrigue KM, Rieck JR, Kennedy KM. et al Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70 (05) 600-6 doi: 10.1001/jamaneurol.2013.1342
• 31 Vagelatos NT, Eslick GD. Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 2013; 35: 152-60 doi: 10.1093/epirev/mxs012
• 32 Dufouil C, Richard F, Fiévet N. et al APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005; 64 (09) 1531-8 doi: 10.1212/01.WNL.0000160114.42643.31